ClinicalTrials.gg

Program

SEL-120

Also written as “RVU120”, “RVU120(SEL120)” and “RVU120 (SEL120)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Primary Myelofibrosis · Myelodysplastic Syndromes, led by 2 companies.

Furthest: phase 2, since Sep 7, 20217 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ryvu Therapeutics62 open or runningphase 2since Sep 7, 2021Jul 12, 2019Dec 2026phase 2 · NCT06987058
GCP-Service International West11 open or runningphase 2since Jan 25, 2024Jan 25, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2019First study: phase 1 study in Leukemia, Myeloid, AcuteNew to Ryvu TherapeuticsRyvu Therapeutics · NCT04021368 · 51 enrolled · United States, Poland
  2. Sep 7, 2021Phase 2 study in RecurrenceRyvu Therapeutics · NCT05052255 · 66 enrolled · Poland, Spain
  3. Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263 · 98 planned · France, Italy, Poland and more
  4. Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06268574 · 62 enrolled · France, Italy, Poland and more
  5. Jan 25, 2024GCP-Service International West's first study: phase 2 study in Low Risk Myelodysplastic SyndromesNew to GCP-Service International WestGCP-Service International West · NCT06243458 · 41 enrolled · France, Germany, Italy and more
  6. Apr 29, 2024Phase 2 study in Primary MyelofibrosisRyvu Therapeutics · NCT06397313 · 36 enrolled · Italy, Poland
  7. May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058 · 14 planned · France, Poland

Ahead

  1. Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058
  2. Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263

TargetBeta

CDK8 →read by rule
“The hydrochloride salt form of romaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), ”NCIt, by rule

Other programs on CDK8

ProgramCompanyFurthest phaseStudies
romaciclibruleRyvu Therapeuticsphase 25

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06987058Leukemia, Myeloid, Acute · France, Poland2By invitationRyvu TherapeuticsDec 202614
NCT06397313Primary Myelofibrosis · Italy, Poland2TerminatedRyvu TherapeuticsJun 30, 202636
NCT06243458Low Risk Myelodysplastic Syndromes · France, Germany, Italy and more2Active, not recruitingGCP-Service International WestMay 202641
NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more2TerminatedRyvu TherapeuticsJun 30, 202562
NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more2RecruitingRyvu TherapeuticsAug 202798
NCT05052255Recurrence · Poland, Spain2TerminatedRyvu TherapeuticsOct 2, 202566
NCT04021368Leukemia, Myeloid, Acute · United States, Poland1TerminatedRyvu TherapeuticsMay 21, 202451

How it is read

Names in the registry

  • “RVU120”, 5 entries
  • “RVU120(SEL120)”, 1 entry
  • “RVU120 (SEL120)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.